Clinical trials: Hospitalized COVID-19
Covid19
INvestigating TELmisartin Study
This study will enroll 40 inpatients hospitalized for COVID-19 at Queens' Medical Center. Participants will be randomized 1:1 to Telmisartan (80 mg) vs placebo to be administered orally once daily x 21 days.
- Trial name
- INTEL (NCT04715763)
- Testing
- Telmisartan Oral Product
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Hawaii
Corona Virus Infection, COVID-19
Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19
Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection.
- Trial name
- BRACE-CORONA (NCT04364893)
- Testing
- Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
- Where
- Brazil
- Volunteers
- 700 people
- Sponsor
- D'Or Institute for Research and Education
COVID-19
Cardiovascular Effects of COVID-19
Cardiometabolic disease may confer increased risk of adverse outcomes in COVID-19 patients by activation of the aldose reductase pathway, a trigger of the inflammatory cascade.
- Trial name
- NCT04365699
- Testing
- AT-001
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- NYU Langone Health
COVID-19
An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19
The observational study will be carried out in two stages. At the first stage, the efficacy and safety of Aprotinin intravenous infusion as add-on therapy to the standard of care will be studied.
- Trial name
- NCT04527133
- Testing
- Aprotinin
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Aviron LLC
Pelvic Inflammatory Disease
Pelvic Inflammatory Disease in COVID-19 Era
The goal of this retrospective cohort study is to to scrutinize the impact of coronavirus disease 2019 (COVID-19) on incidence, demography and patient characteristics in Pelvic Inflammatory Disease comparing with the equal time…
- Trial name
- NCT05648747
- Testing
- impact of COVID-19 on Health-Seeking Behaviors
- Where
- Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Università degli Studi di Ferrara
COVID-19
PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19
Open label controlled clinical trial to evaluate the safety and efficacy of the use of convalescent plasma in hospitalized patients with COVID-19 infection.
- Trial name
- NCT04497324
- Testing
- Convalescent plasma
- Where
- 2 sites in Peru
- Volunteers
- 100 people
- Sponsor
- Universidad Peruana Cayetano Heredia
COVID-19 Pneumonia
Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults
Techfields Inc. is developing a new investigational prodrug as a topical spray, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19.
- Trial name
- NCT05212818
- Testing
- TF0023
- Where
- 5 sites in United States, South Africa
- Volunteers
- 19 people
- Sponsor
- Techfields Inc
SARS-COV2 Infection, COVID-19 Disease
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
Effect of Covid-19 disease in clotting factors levels in hospitalized patients
- Conditions
- SARS-COV2 Infection, COVID-19 Disease, Hospitalized Patients
- Trial name
- NCT04787510
- Testing
- low molecular weight Heparin as standard of care treatment
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- University Hospital, Ioannina
SARS-CoV-2 Infection
COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19
In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like, investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2 infection meeting inclusion and exclusion criteria, will…
- Trial name
- COVIDMED (NCT04328012)
- Testing
- Losartan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bassett Healthcare
COVID-19
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a…
- Trial name
- CONCOR-1 (NCT04348656)
- Testing
- Convalescent plasma
- Where
- 73 sites in United States, Brazil and 1 more
- Volunteers
- 940 people
- Sponsor
- Hamilton Health Sciences Corporation
Covid19
Outpatient Liquid Aspirin (OLA)
The purpose of this study is to obtain reliable and interpretable data to inform future trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID -19 associated coagulopathy (CAC) .
- Trial name
- OLA COVID (NCT04937088)
- Testing
- ASA
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Hospitalization
Observational Study in COVID-19 Patients Treated With Remdesivir
Taking into account the high number of COVID-19 patients managed in Italian Internal Medicine, Fadoi Foundation (Italian Scientific Society of Internal Medicine) promotes a national retrospective observational study in patients…
- Trial name
- RECOVER (NCT05239988)
- Testing
- no experimental intervention
- Where
- 30 sites in Italy
- Volunteers
- 1,004 people
- Sponsor
- Fadoi Foundation, Italy
Covid19, Pneumonia
Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
Viral infections provoke the systemic inflammatory response and cause an imbalance between the procoagulant and anticoagulant homeostatic mechanisms.
- Conditions
- Covid19, Pneumonia, Coagulation Disorder, Pulmonary Embolism
- Trial name
- NCT04508439
- Testing
- Enoxaparin
- Where
- Mexico
- Volunteers
- 130 people
- Sponsor
- Hospital Regional de Alta especialidad de Ixtapaluca
Covid19
Viral Shedding, Symptoms and Exposure of SARS-CoV-2 in Non-hospitalized Children With COVID-19
Data on COVID-19 in children are still scarce, and their role in SARS-CoV-2 transmission is poorly described. Furthermore, documentation of the best SARS-CoV-2 sampling methods in children are limited.
- Trial name
- NCT04666207
- Testing
- PCR
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Coronavirus Infection
COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19
The most prevalent complication of COVID-19 infection is respiratory failure from severe acute respiratory syndrome (SARS), the leading cause of mortality.
- Trial name
- COMBATCOVID19 (NCT04363437)
- Testing
- Colchicine, Usual Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Maimonides Medical Center
Intensive Care Unit Syndrome, Covid19
Evaluation of Psychological Impact of Group Therapy for Patients Who Have Been Hospitalized in Intensive Care During COVID-19 Pandemic: Exploratory Study
Psychological impact of intensive care hospitalization for patients has been demonstrated during the last few years: anxiety, depression and post traumatic stress disorder.
- Conditions
- Intensive Care Unit Syndrome, Covid19, Anxiety, Depression
- Trial name
- GPR COVID (NCT04747405)
- Testing
- therapy group
- Where
- France
- Volunteers
- 59 people
- Sponsor
- Centre Hospitalier Metropole Savoie
COVID-19
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.
- Trial name
- NCT04470622
- Testing
- Aprepitant injectable emulsion
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Heron Therapeutics
COVID19 Infection
Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19
The study hypothesis is that cyclosporine, added to standard treatment of hospitalized patients with COVID19 infection may improve their prognosis.
- Trial name
- NCT04392531
- Testing
- Cyclosporine, Standard treatment
- Where
- 7 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Covid19
A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19
The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.
- Trial name
- B-EPIC (NCT04796402)
- Testing
- Bamlanivimab, Standard of Care
- Where
- Canada
- Volunteers
- 576 people
- Sponsor
- Fraser Health
COVID-19
A Clinical Trial for Hospitalized Patients With COVID-19 in Ceará: ResCOVID Study
This is a case series of patients with COVID-19 admitted to the northeast Brazil region, in a referenced hospital for COVID-19, during the 2020 COVID-19 pandemic. Data will be collected prospectively and retrospectively.
- Trial name
- ResCOVID (NCT04649827)
- Testing
- Clinical Observation
- Where
- Brazil
- Volunteers
- 3,000 people
- Sponsor
- Escola de Saúde Pública do Ceará